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Abstract
Migraine is a leading cause of disability worldwide, but it is still underdiagnosed and undertreated. Research on the
pathophysiology of this neurological disease led to the discovery that calcitonin gene-related peptide (CGRP) is a
key neuropeptide involved in pain signaling during a migraine attack. CGRP-mediated neuronal sensitization and
glutamate-based second- and third-order neuronal signaling may be an important component involved in migraine
pain. The activation of several serotonergic receptor subtypes can block the release of CGRP, other neuropeptides,
and neurotransmitters, and can relieve the symptoms of migraine. Triptans were the first therapeutics developed for
the treatment of migraine, working through serotonin 5-HT1B/1D receptors. The discovery that the serotonin 1F (5-
HT1F) receptor was expressed in the human trigeminal ganglion suggested that this receptor subtype may have a
role in the treatment of migraine. The 5-HT1F receptor is found on terminals and cell bodies of trigeminal ganglion
neurons and can modulate the release of CGRP from these nerves. Unlike 5-HT1B receptors, the activation of 5-HT1F
receptors does not cause vasoconstriction.
The potency of different serotonergic agonists towards 5-HT1F was correlated in an animal model of migraine (dural
plasma protein extravasation model) leading to the development of lasmiditan. Lasmiditan is a newly approved
acute treatment for migraine in the United States and is a lipophilic, highly selective 5-HT1F agonist that can cross
the blood-brain barrier and act at peripheral nervous system (PNS) and central nervous system (CNS) sites.
Lasmiditan activation of CNS-located 5-HT1F receptors (e.g., in the trigeminal nucleus caudalis) could potentially
block the release of CGRP and the neurotransmitter glutamate, thus preventing and possibly reversing the
development of central sensitization. Activation of 5-HT1F receptors in the thalamus can block secondary central
sensitization of this region, which is associated with progression of migraine and extracephalic cutaneous allodynia.
The 5-HT1F receptors are also elements of descending pain modulation, presenting another site where lasmiditan
may alleviate migraine. There is emerging evidence that mitochondrial dysfunction might be implicated in the
pathophysiology of migraine, and that 5-HT1F receptors can promote mitochondrial biogenesis. While the exact
mechanism is unknown, evidence suggests that lasmiditan can alleviate migraine through 5-HT1F agonist activity
that leads to inhibition of neuropeptide and neurotransmitter release and inhibition of PNS trigeminovascular and
CNS pain signaling pathways.
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Background
Migraine is a painful, disabling neurological disease that
has long afflicted the population worldwide. It was only
in the past few decades that inroads have been made
into understanding the pathophysiology of migraine and
that specific treatments for migraine were developed [1].
The vascular theory of migraine held that the disorder
was caused by vasodilation of meningeal arteries [1].
Based on this prevailing viewpoint, the prototypic trip-
tan, sumatriptan, was initially developed to treat mi-
graine due to its vasoconstrictive properties. The clinical
success of sumatriptan led to the introduction of
second-generation triptans and spurred an increased re-
search effort into understanding the pathophysiology of
migraine.
Numerous studies have since provided convincing evi-
dence that migraine is a neurological disease with a
prominent role in the activation of the trigeminovascular
system (Fig. 1a, Supplemental Video). It was also deter-
mined that calcitonin gene-related peptide (CGRP), a
neuropeptide prominently expressed in trigeminal affer-
ent neurons, plays a key role in the neurophysiology of
migraine (Fig. 2a, Supplemental Video) [2–4]. Research
has shown that the triptans exert their antimigraine ef-
fects by blocking the release of CGRP and potentially
other neuropeptides from trigeminal afferent fibers. The
triptans appear to work through activation of the seroto-
nergic 5-HT1B/D receptors rather than vasoconstriction
[2, 3, 5]. The vasoconstrictive effect is mediated through
the 5-HT1B receptor [5].
Triptans are generally considered safe overall, but they
are contraindicated in patients with uncontrolled hyper-
tension and other cardiovascular and cerebrovascular dis-
eases [6]. The triptans vary somewhat in their ability to
cross the blood-brain barrier (BBB). Data suggests that
overall, the triptans seem to remain largely restricted to
peripheral nervous system (PNS) sites of action [6]. How-
ever, recent evidence in rats suggests that subcutaneous
sumatriptan can accumulate rapidly in the central nervous
system (CNS) [7, 8]. The development and clinical efficacy
of non-vasoconstriction drugs for the treatment of mi-
graine led to the conclusion and current predominate the-
ory that vasoconstriction is not the triptan’s therapeutic
mechanism of action. Attempts to develop 5-HT1D ago-
nists to treat migraine were largely unsuccessful; and a
newly recognized class of drugs, the “ditans,” was devel-
oped to selectively act at the 5-HT1F receptor.
With its approval in October 2019 in the United
States, lasmiditan is currently the only selective 5-HT1F
agonist approved for treatment of acute migraine attack.
Lasmiditan is considered a first-in-class “ditan” based
upon its unique chemical structure with a pyridinoylpi-
peridine scaffold structure, 2,4,6-trifluoro-N-[6-(1-
methylpiperidine-4-carbonyl)pyridine-2-yl] benzamide
hemisuccinate, and its selective high affinity for the 5-
HT1F receptor. Preclinical studies showed that lasmidi-
tan is devoid of vasoconstrictive effects [9] and that it
penetrates the BBB into the CNS [10], which is import-
ant since the CNS also plays a role in the management
of migraine [11]. Lasmiditan has shown efficacy in the
acute treatment of migraine in randomized, double-
blind, placebo-controlled clinical trials (RCT) [12–15].
This narrative review highlights the pharmacology and
pharmacokinetics of lasmiditan and its pharmacological
activity at the 5-HT1F receptor as well as the role of the
5-HT1F receptor as a potential mechanism to be
exploited in treating migraine.
This review discusses the potential mechanism of ac-
tion for lasmiditan in the context of overall migraine
pathophysiology. Data supports that migraine patho-
physiology involves activation of the hypothalamus, pro-
ducing the prodrome phase premonitory symptoms of
migraine that are followed by trigeminal ganglion (TG)
activation, which leads to the headache phase [16]. Tri-
geminal system activation results in the release of mul-
tiple neuropeptides, including CGRP, pituitary adenylate
cyclase-activating polypeptide (PACAP), and substance
P, at both the PNS and CNS terminals of the trigeminal
nerve [17]. CGRP has been shown to be involved in mi-
graine [2]. Preclinical and clinical studies failed to sup-
port a role for substance P in migraine. Although
substance P and CGRP are co-localized in pre-synaptic
vesicles and released together [18], trials assessing agents
that block only substance P have not shown benefit in
the treatment of migraine [19, 20]. Conversely, emerging
evidence suggests that PACAP may contribute to mi-
graine [17, 21].
Afferent activation of the trigemino-thalamic pathway
and sensory cortex leads to sensitization and allodynia,
which can lead to chronification – progression in fre-
quency of migraine attacks [16, 22]. The CNS afferent
pathways involve the excitatory neurotransmitter glu-
tamate. The ascending CNS pain pathways are modu-
lated by descending pain modulatory pathways that
include projections to the periaqueductal gray matter
(PAG), noradrenergic locus coeruleus, and the nucleus
raphe magnus (NRM). The descending pathways relay
serotonergic and non-serotonergic pain inhibitory and
facilitatory neural projections [23–27]. Inhibitory projec-
tions can attenuate pain signaling likely in part by acti-
vating 5-HT1F receptors on glutamate-containing
neurons [3, 24]. These anatomic and neuronal signaling
pathways could be potential neurological points of activ-
ity for ditan therapy.
Literature search methods
The PubMed, Embase, and Cochrane Library databases
were searched for the terms “LY573144, lasmiditan, OR
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Fig. 1 a Trigeminal and pain pathways associated with pain signaling during a migraine attack plus 5-HT1F receptor locations in PNS and CNS
areas involved in the pathophysiology of migraine. b Activation of trigeminal and pain pathways during a migraine attack; sustained or repeated
activation of pain pathways leads to increasing sensitivity of trigeminal neurons in the brain stem. c Activated nerves release various substances
including neuropeptides and neurotransmitters such as CGRP and glutamate that can exacerbate neurogenic inflammation and nociceptor pain
signaling in migraine; this may hyperexcite neurons to propagate pain responses and enhance central sensitization. d In addition to other
endogenous inhibitory processes, serotonin from pain modulating pathways activates 5-HT receptors that can inhibit neuropeptide and
neurotransmitter release, thereby inhibiting their local activity and downstream neuronal signaling; however, these modulatory mechanisms may
be disturbed in migraine pathophysiology, predisposing patients with migraine to an attack. e Lasmiditan crosses the blood-brain barrier and
presumably acts in both the PNS and the CNS to selectively activate 5-HT1F receptors to inhibit the release of neuropeptides and
neurotransmitters such as CGRP and glutamate, thereby inhibiting their local activity and migraine attack pain pathways. f Preclinical and ex vivo
human evidence suggests that lasmiditan inhibits PNS trigeminal nerve and CNS pain signaling pathways, exerting therapeutic effects in the
treatment of migraine without causing vasoconstriction. Abbreviations: CNS, central nervous system; mRNA, messenger ribonucleic acid; PNS,
peripheral nervous system. Note: 5-HT1F receptor locations are based on human and animal mRNA, immunohistochemistry, and functional
biology studies
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LY334370 OR (COL-144 OR COL144 OR COL 144).”
The terms included variations of the “LY” numbers to
include hyphens, commas, or spaces, and LY334370 was
included since it was a 5-HT1F receptor agonist that pre-
ceded lasmiditan in development. A separate search was
conducted for “(5-HT OR serotonin) AND (mechanism
OR mechanism of action) AND (blood brain barrier)
AND (central penetrant) AND (physiology OR patho-
physiology OR pharmacology) AND (lasmiditan OR
ditan).” Results were examined to identify primary
sources that address the basic pharmacology of 5-HT1F
agonists or their potential role in the PNS and CNS in
treating migraine. Review articles published in 2018 and
2019 were examined to find any primary sources that
may have been missed in the searches. Review articles
are included in this manuscript to support ancillary
points, to support tangential facts, and to buttress argu-
ments. This is a comprehensive and balanced overview
Fig. 2 a Neuropeptides and neurotransmitters regulate pain during a migraine attack. Nerve activity in the trigeminovascular pain pathway leads
to the release of neuropeptides and neurotransmitters, such as CGRP and glutamate that can hyperexcite neurons, thereby propagating PNS and
CNS pain responses. b The thalamic trigeminovascular neurons, trigeminal ganglion, and the trigeminal nucleus caudalis are densely innervated
with serotonergic neurons. Subtypes of serotonin (5-HT) receptors found in these areas, such as 5-HT1F, are believed to be involved in the
pathophysiology of migraine. Serotonin receptor agonists are the foundation of many acute treatments for migraine; however, many of these
therapeutics are associated with vasoconstriction through activation of 5-HT1B receptors. Serotonin binding to 5-HT1F receptors can inhibit
presynaptic vesicular release of CGRP and inhibit postsynaptic cAMP signaling cascades. Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); 5-
HT1, 5-hydroxytryptamine 1 receptor; cAMP, cyclic adenosine monophosphate; CGRP, calcitonin gene-related peptide; CNS, central nervous
system; PNS, peripheral nervous system
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of the current understanding of the role of 5-HT1F in
migraine pathophysiology; therefore, all relevant studies
may not be specifically referenced.
PNS and CNS neuropathology of migraine
Research in the mid-1600s proposed that migraine was
caused by meningeal vasodilation, a view that persisted
through the 1900s [1]. An alternate theory that migraine
arose from “nerve storms evolved out of the optic thal-
amus,” was put forth in 1783 [1]. The current working
hypothesis of migraine is that it is a complex neuro-
logical disease that is mediated through the trigemino-
vascular system (Fig. 1b, Supplemental Video) [28–30].
Some studies that correlated observations made in ani-
mal models with clinical observations, including imaging
studies, suggested that the headache phase of a migraine
attack corresponds to the development of peripheral
sensitization involving the primary afferents from the
TG (Fig. 1c, Supplemental Video) [31–33]. As the attack
progresses, central sensitization of the trigeminal nucleus
caudalis (TNC) occurs, with enhanced responses of noci-
ceptive TNC neurons, and expansion of receptive fields to
facial areas. The TNC has extensive connections with
other brain regions. Prolonged activation of the TNC re-
sults in sensitization of third-order neurons in the thal-
amus, which can account for the expansion of cutaneous
allodynia to extracephalic regions [31, 33–36]. The TNC
also has reciprocal connections with brain regions that are
implicated in pain processing, such as the insula, PAG,
and the rostral ventromedial medulla [37]. Further pro-
gression of central sensitization results in sensitization of
thalamic third-order neurons receiving inputs from the
TNC; this is associated with the spreading of cutaneous
allodynia to extracephalic regions [31, 33]. For example,
enhanced activation of the posterior thalamus in response
to light cutaneous stimuli applied to the dorsum of the
hand of a patient during a migraine attack was demon-
strated in one functional magnetic resonance imaging
(fMRI) study. The shift from peripheral sensitization to
central sensitization may be demonstrated by the coinci-
dent loss of efficacy of triptans in reversing a migraine
headache as the migraine attack progresses, as many of
these therapeutics generally do not appear to act centrally
[38].
Recent reviews suggested that the genesis of a mi-
graine attack remains a mystery [24, 25, 39]. It has been
proposed that cortical spreading depression (CSD), a
wave of depolarization and repolarization across the cor-
tex, may trigger neurogenic inflammation, with plasma
extravasation and mast cell degranulation. Previous
speculations have associated migraine with disruption of
the BBB [40]; however, more recent clinical observations
showed that the BBB remains intact during a migraine
attack [41, 42]. Animal models were developed to study
these ideas, but it is unclear to what extent they repre-
sent the clinical situation. CGRP can degranulate mast
cells in rats, but human mast cells do not have func-
tional CGRP receptors and are not responsive to CGRP
[43]. Moreover, spontaneous CSD has not been demon-
strated in humans, and there are no studies proving that
CSD leads to a migraine attack [44].
Imaging studies showed activation of the hypothalamic
areas when migraine is provoked by injections of nitrogly-
cerin or CGRP that produce the premonitory symptoms
of the prodrome phase before the headache starts. This is
consistent with premonitory symptoms such as food crav-
ing, fatigue, nausea, and yawning which suggest hypothal-
amic involvement in migraine [16, 45]. Studies using
H2
15O positron emission tomography (PET) cerebral
blood flow scans showed increased hypothalamic activity
during the early prodrome phase in patients who had mi-
graine induced with nitroglycerin [46]. Increased hypo-
thalamic activity along with functional coupling to the
TNC was detected by fMRI in a patient who experienced
two to three migraine attacks per month and underwent
daily scans for 30 days [47]. It is believed that oscillations
in hypothalamic activity alter functional connections be-
tween the hypothalamus and brainstem, altering suscepti-
bility thresholds to sensory stimuli thereby initiating and
ending a migraine attack [48]. Another view [24, 45] sug-
gested that cortical excitability influences activity at other
sites, including pain modulatory systems, to initiate mi-
graine. A central locus for the initiation of migraine is
consistent with the fact that the premonitory symptoms
that precede headache can occur many hours before the
pain. Peripheral sensitization can develop as a result of en-
hanced CNS activity through as yet undetermined mecha-
nisms, but possibly involving oscillations in hypothalamic
activity, eventually resulting in migraine headache pain
[16, 24, 45, 48]. These data point to the importance of the
CNS as a potential target tissue for migraine therapy.
Role of CGRP in migraine
During the initial phase of a migraine attack, CGRP is
released from trigeminal afferent C-fibers that are bi-
directional. This released CGRP can activate the CGRP
receptors on adjacent trigeminal afferent Aδ fibers that
are bi-directional and project back to the TNC (Fig. 2a).
While CGRP does not produce nociception, it can pro-
mote central sensitization of the TNC second-order neu-
rons. CGRP released in the PNS can dilate the
meningeal arteries due to its potent vasodilatory effect,
but it also activates signaling cascades that produce ni-
tric oxide (NO) and release glutamate and prostaglan-
dins from the arterial wall. These substances can
sensitize and/or activate the trigeminal afferent fibers of
the PNS, leading to enhanced release of CGRP and pro-
moting a feed-forward enhancement mechanism.
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Activation of these PNS nociceptors is an important step
in the early phase of the migraine headache [2, 24, 25].
Continued activation of the primary afferents in the
TNC, together with the release of CGRP, as well as glu-
tamate and possibly other neurotransmitters, promotes
sensitization of these second-order neurons [49–51].
Central sensitization, driven in large part by the excita-
tory neurotransmitter glutamate, is associated with re-
duced activation thresholds, increased firing in response
to inputs, continued after-discharge in response to in-
puts, recruitment of adjacent neurons, and expansion of
their fields [31, 33–36, 49, 51]. This mechanism can ac-
count for the development of cutaneous allodynia and
its expansion in facial regions. Whereas the role of
CGRP in the trigeminovascular system is well examined
regarding migraine, how or whether CGRP is instrumen-
tal at CNS sites requires further investigation.
The small molecule CGRP antagonist, telcagepant,
does not appear to act centrally at therapeutic doses
[52]. The small molecule GGRP receptor antagonists
such as ubrogepant and rimegepant, which were recently
approved in the United States for the treatment of mi-
graine attacks [53, 54], appear to predominantly function
in the PNS [24, 55]. While the BBB is relatively imper-
meable to antibodies [56], it is still possible to detect up
to approximately 0.1% of the blood concentration in the
cerebrospinal fluid [24, 57, 58]; thus, the monoclonal
antibodies to CGRP peptide (eptinezumab, fremanezu-
mab, and galcanezumab) could potentially have some
level of CNS activity, despite not appearing to penetrate
the BBB in large concentrations [24, 57]. These data sug-
gest that there is a need for migraine therapeutics that
could act in the CNS. Importantly, the activity of CGRP
at CNS sites (e.g., amygdala, PAG, parabrachial nucleus,
and NRM) can be either pronociceptive or antinocicep-
tive, depending on the brain region involved, suggesting
that the role of CNS CGRP in migraine may be complex
[24, 25, 59].
5-HT1F receptor location
The human 5-HT1F receptor was first identified and
cloned in 1993 [60]. Messenger RNA (mRNA) for the 5-
HT1F receptor was found in human brain, uterine, and
mesenteric tissue, but not in heart, kidney, liver, pan-
creas, spleen, or testes. In situ hybridization showed the
presence of mRNA in the cerebral cortex, hippocampus,
and dorsal raphe of guinea pig brains [60] and in the
guinea pig and human TG [61–63]. In other studies,
mRNA for 5-HT1F was detected in human cerebral
blood vessels [61], rat meningeal dura mater [64], cere-
bral cortex, and TG [65]. Moderate levels were detected
in coronary and pulmonary blood vessels, but not in
skeletal muscles or the mesenteric artery [65]. Studies
performed with isolated human microvasculature
detected 5-HT1F message in microvessels and capillar-
ies, but not in cultures of isolated human brain
smooth muscle cells, suggesting that the 5-HT1F re-
ceptors were present on astrocytes associated with the
vessels [66].
Autoradiographic in situ hybridization studies per-
formed with guinea pig brain sections showed the
presence of mRNA for 5-HT1F receptors in several re-
gions. These included cortical and hippocampal sites,
the claustrum, amygdala, the mediodorsal and latero-
dorsal thalamic nuclei, supraoptic hypothalamic nu-
cleus, periventricular hypothalamic area, and several
midbrain and medullary sites including the dorsal
raphe, anterior pretectal area, ventral tegmental nu-
cleus, paragigantocellular reticular nucleus, and the
TNC [67].
Prior to the availability of selective ligands for 5-HT1F,
triptans were used to visualize the distribution of 5-HT1F
receptors as some triptans bind to 5-HT1F in addition to
5-HT1B/D. Autoradiographic studies with [
3H]-sumatrip-
tan, with and without 5-carboxamidotryptamin (5-CT)
used to displace sumatriptan from 5-HT receptors,
showed the presence of the 5-HT1D and 5-HT1F receptor
subtypes in the human frontal cortex, globus pallidus,
PAG, and TNC [68]. Autoradiography in rats and guinea
pigs showed the presence of 5-HT1F in the PAG, TNC,
hippocampus, and cortex [69, 70]. Autoradiographic sig-
nals in the human brain were observed at high levels in
the globus pallidus and substantia nigra, moderate levels
in the fronto-temporal cortex, caudate-putamen and
hippocampus, and low levels in the cerebellum, pons, me-
dulla, and spinal cord [71].
LY334370 is a high affinity, selective agonist that acts
at the 5-HT1F receptor with approximately 300-fold
greater selectivity compared to other 5-HT receptors
[72] and is a useful pharmacologic tool for examining
the 5-HT1F receptor [72]. Thus, [
3H]LY334370 was used
for autoradiographic studies performed on guinea pig
and rat brains, and preliminary studies (N = 1 each) with
rhesus monkey and human brain sections [72]. In those
studies, specific binding sites were detected in the cor-
tex, amygdala, thalamus, nucleus accumbens, caudate
putamen, hippocampal CA3 region, olfactory bulb, and
tubercle of the rat, as well as in the cortex, caudate puta-
men, nucleus accumbens, thalamus, and medial
mammillary nucleus of the guinea pig [72].
Based on currently described human and animal
mRNA, immunohistochemistry, and functional biology
studies, 5-HT1F receptor locations are on neuronal
synapses within PNS and CNS structures involved in the
pathophysiology of migraine and structures modulating
associated pain signaling, including but not limited to
meninges, TG, trigeminal nucleus caudalis, hypothal-
amus, thalamus, and cortex (Fig. 1a) [72–76].
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Role of 5-HT1F receptor in migraine
Nerve activity in the trigeminovascular pain pathway leads
to the release of neuropeptides and neurotransmitters,
such as CGRP and glutamate, and this activity is thought
to exacerbate neurogenic inflammation and nociceptor
pain signaling in migraine (Fig. 1c) [24, 77, 78]. The re-
lease of CGRP and glutamate can hyperexcite second-
order neurons, which may propagate PNS and CNS pain
responses [24, 77, 78]. The 5-HT1F receptors are located
on neuronal synapses involved in this modulating of pain
signaling (Fig. 2b, Supplemental Video) [74, 75].
Dose-dependent inhibition of forskolin-induced cyclic
adenosine monophosphate (cAMP) formation by 5-HT1F
agonists showed that the 5-HT1F receptor, like other
subtypes in the 5-HT1 family, is coupled to the Gi/o G-
protein and, when activated, inhibits adenylate cyclase-
mediated formation of cAMP (Fig. 2b). This inhibits the
phosphorylation of protein kinase A (PKA) and affects
downstream signaling pathways, including the inhibition
of neuropeptide and neurotransmitter release [60]. Evi-
dence suggests that serotonin activity at the 5-HT1F re-
ceptor on neuronal synapses inhibits the release of
CGRP and glutamate, reducing hyperexcitability and
regulating pain signaling (Fig. 2b, Fig. 1d, Supplemental
Video) [24, 77].
Immunohistochemical studies of cervical, thoracic, and
lumbar dorsal root ganglia (DRG) and TG of rats with
antibodies selective for 5-HT1B, 5-HT1D, or the 5-HT1F
receptors showed that the majority of DRG and TG neu-
rons were labelled for each of the subtypes. Immunola-
beling was noted on small-diameter C-fiber neurons, Aδ
neurons, and the larger Aβ neurons [73]. Double-
labelling immunohistochemistry of TG in rats found that
the majority of neurons that were positive for glutamate
also expressed the 5-HT1B (64%), 5-HT1D (68%), and the
5-HT1F (60%) receptor [79]. These three receptors are
situated such that they can modulate the release of glu-
tamate from CNS terminals of the TG neurons. Glutam-
ate has been shown to mediate trigeminovascular
nociceptive transmission through N-methyl-D-aspartate
(NMDA) and non-NMDA receptors in the TNC [49],
and it is an important neurotransmitter in the develop-
ment and maintenance of central sensitization. Thus, in-
hibition of glutamate release in the TNC via 5-HT
receptor activation may not only attenuate early stages
of migraine headache, but may reduce glutamate effects
during the later stages where central sensitization and
cutaneous allodynia are believed to occur [31, 33–36] .
Double-labeling studies performed in the vestibular nu-
clei of rats revealed that neurons positive for glutamate
[80] or CGRP [81] also expressed label for the 5-HT1F
receptor, providing additional evidence that activation of
this receptor may inhibit the release of glutamate and
CGRP in CNS sites.
Imaging studies have implicated several brain regions
in migraine, including the thalamus PAG, and the TNC
[24, 82]. Expression of 5-HT1F receptors in the thalamus
represents another site where a 5-HT1F agonist might
contribute to an anti-migraine effect, possibly in part by
preventing or reversing central sensitization; however,
this has not been confirmed or refuted by any studies.
The midbrain PAG is a region that is intricately linked
to analgesia, and also may contribute to migraine [83].
Early clinical studies with electrical stimulation of the
PAG produced relief of otherwise intractable pain [84].
Unexpectedly, some patients also developed migraine-
like headaches after implantation of the electrodes into
the PAG [84]. fMRI studies have shown activation of the
PAG during a migraine attack. The microinjection into
the PAG of naratriptan, which has equivalent affinity for
the 5-HT1B, 5-HT1D, and 5-HT1F receptors [52], pro-
duced a seemingly selective inhibition of TNC neurons
to meningeal stimuli, but not cutaneous facial stimuli
[85]. In that study, the evoked responses of TNC neu-
rons were recorded in response to stimuli applied to the
dura, facial skin, and cornea. Microinjection of naratrip-
tan into the PAG inhibited nociceptive inputs in the
TNC from dural, but not facial or corneal nociceptive
stimuli [85]. Although this study focused on the poten-
tial role of 5-HT1B/1D receptors in modulating TNC neu-
rons from the PAG, the potential role of 5-HT1F
receptors was not excluded.
Migraine involves activation of PNS nerve endings that
send signals from the dural meninges covering the brain to
the TG; then the signal is propagated to CNS brain stem nu-
clei such as the trigeminal nucleus caudalis, followed by sig-
naling to the hypothalamus and thalamus and ascending
signals to the cortex (Fig. 1a,b,c) [72–76, 82]. When sero-
tonin binds to the 5-HT1F receptor, it inhibits neuropeptide
and neurotransmitter release, inhibiting transmitter local ac-
tivity and downstream neuronal signaling (Fig. 2b, Fig. 1d)
[74, 75, 81, 86].
Lasmiditan mechanism of action
5-HT1F agonists similar to Lasmiditan
Compounds LY344864 and LY334370 are selective ligands
for the 5-HT1F receptor that were not commercialized as
clinical therapies but are useful pharmacologic tools for
the characterization of this receptor. LY344864 binds to
the cloned human 5-HT1F receptor with a Ki of 6 nM, and
with poor affinity (≥500 nM) for other serotonergic recep-
tors [87]. LY344864 inhibited forskolin-induced accumu-
lation of cAMP and inhibited plasma extravasation in rats
[87]. Whereas LY344864 did not produce any contractions
of rabbit saphenous vein up to a concentration of 10− 4M,
the triptans: sumatriptan, zolmitriptan, rizatriptan, and
naratriptan, all produced contractions, suggesting vaso-
constrictive activity [9]. CNS penetration of a single
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peripheral dose of LY344864 (1mg/kg, IV) was indicated
by persistent cortical levels detected over 8 h [87]. System-
ically administered LY344864 inhibited c-fos expression in
the TNC of rats in response to intracisternal administra-
tion of capsaicin [88]. Increased expression of the immedi-
ate early gene c-fos or of its protein product Fos is a
reliable biomarker of nociceptive stimulation, while inhib-
ition of c-fos expression and TNC neuronal activity are
suggestive of a CNS-mediated effect [52].
LY334370 is also a highly selective agonist for the 5-
HT1F receptor, with a KD of 0.446 nM for the human 5-
HT1F receptor [89]. There was a statistically significant
correlation between [35S] GTP binding of LY334370 in
cell homogenates expressing the 5-HT1F receptor and
forskolin-stimulated cAMP formation as well as with
plasma protein extravasation caused by electrical stimu-
lation of meninges [89, 90]. In addition, LY334370 inhib-
ited Fos expression in the TNC and reduced neuronal
firing rates of TNC neurons in response to dural stimuli,
suggesting a potential CNS-mediated effect [52, 88].
LY334370 did not induce contractions in the rabbit sa-
phenous vein either alone or in the presence of a base-
line vascular tone induced by PGF2α [52], and LY334370
did not constrict human meningeal and cerebral arteries
in vitro [91]. This compound was found to be effective
and well tolerated for the acute treatment of episodic
migraine [52, 91]. Adverse events (AE) included asthe-
nia, dizziness, and somnolence, which suggest that
LY334370 acts at CNS sites. It was not commercially de-
veloped, however, as preclinical toxicology results sug-
gested potential off-target liver toxicity [52].
Lasmiditan
Lasmiditan (formerly COL-144, LY573144) is a first-
in-class “ditan” compound that has a pyridinoyl-
piperidine scaffold and differs from LY334370 and
triptans by the absence of an indole core [92]. Lasmi-
ditan is a selective 5-HT1F agonist approved in the
US for the acute treatment of migraine with or with-
out aura in adults [93]. It is highly selective for the
human 5-HT1F receptor, with a Ki of 2.21 nM, com-
pared to values of 1053 nM, 1043 nM, and 1357 nM
for the 5-HT1A/B/D receptors, respectively [92]. Lasmi-
ditan has greater than 440 times more potent binding
affinity for 5-HT1F versus 5-HT1B and 5-HT1D recep-
tors. Lasmiditan showed no discernable agonist activ-
ity at the 5-HT1B/D receptors as determined by
stimulation of [35S]-GTPγS binding, but had nanomo-
lar efficacy at the 5-HT1F receptor in this assay [92].
In a recent study where second-messenger activity of
receptor activation was analyzed, it was found that
almotriptan, avitriptan, eletriptan, frovatriptan, nara-
triptan, sumatriptan, and zolmitriptan showed varying
magnitudes of agonist activity at the 5-HT1B/D as well
as the 5-HT1F receptors, whereas lasmiditan only
showed agonist activity at the 5-HT1F receptor [94].
In studies performed with several structurally diverse
serotonergic agonists, there was a significant correlation
between contractile potency in either the rabbit or ca-
nine saphenous vein with potency for contraction of hu-
man cerebral arteries, suggesting that the saphenous
vein assay may be predictive of human vasoconstrictive
activity [95]. Lasmiditan has no discernable vasocon-
strictive effects at concentrations up to 100 μM in the
rabbit saphenous ring assay, which is a reliable predictor
of human coronary artery vasoconstrictor liability [92].
More recently, the activity of lasmiditan in isolated hu-
man coronary arteries, internal mammary arteries, and
middle meningeal arteries was compared to that of su-
matriptan [94]. Lasmiditan did not produce any signifi-
cant contractions at all doses tested in these isolated
human arteries, whereas dose-dependent contractions
occurred with sumatriptan. In in vivo studies in anesthe-
tized beagles, lasmiditan did not decrease carotid artery
diameter or blood flow at clinically relevant doses [94].
Activation of second messenger for the 5-HT1B receptor,
but not for the 5-HT1D or the 5-HT1F receptors, corre-
lated significantly with contractile potency [94]. These
in vitro human isolated blood vessel and in vivo anesthe-
tized canine results suggest that, unlike triptans, lasmidi-
tan is not vasoconstrictive at active doses.
In one study, dilation of the middle meningeal artery
in response to endogenously released CGRP via either
capsaicin injection or periarterial electrical stimulation,
as well as to exogenously administered CGRP, was mea-
sured in anesthetized rats [96]. Lasmiditan (0.3–10mg/
kg) or sumatriptan (3–10 mg/kg) produced significant
(p < 0.05) dose-dependent inhibition of endogenous but
not exogenous CGRP, indicating that lasmiditan can in-
hibit dural CGRP release but is not a CGRP receptor an-
tagonist [96]. Unlike sumatriptan, lasmiditan did not
produce any significant blood pressure changes [96]. In
other studies, lasmiditan blocked electrical stimulation
of trigeminal afferent neurons innervating the dura acti-
vated TNC neurons [76]. Lasmiditan that was orally ad-
ministered 1 h prior to electrical stimulation of the TG
of anesthetized rats inhibited dural plasma protein ex-
travasation in a dose-dependent manner [92]. In
addition, orally-administered doses of lasmiditan blocked
the expression of c-fos in the TNC in response to elec-
trical stimulation of the TG [92]. Together with the ab-
sence of vasoconstrictive effect, these preclinical results
showed that lasmiditan has high potency and efficacy at
the 5-HT1F receptor, but not the 5-HT1B or 5-HT1D
receptors.
The induced expression of Fos in the TNC is a marker
of nociceptive activation of the second-order neurons,
and is mediated largely through glutamate released from
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trigeminal nerve terminals in the TNC [97]. Moreover,
glutamate release drives central sensitization in the
TNC [98]. Consequently, lasmiditan may alleviate mi-
graine at least in part by activation of 5-HT1F receptors
present on glutaminergic trigeminal nerve terminals in
the TNC [79].
RCTs have demonstrated that lasmiditan is efficacious,
safe, and generally well tolerated for the acute treatment
of migraine. In a proof-of-concept, multi-center trial
(NCT00384774), intravenous (IV) doses of 10 mg to 40
mg of lasmiditan resulted in pain-free rates at 2 h ran-
ging from 20.8% (10 mg) to 37.5% (30 mg), compared to
a 19% rate for placebo [99]. The response rates, based
on patients reporting reduction in headache severity
from moderate or severe at baseline to mild or no head-
ache, were 54% to 75% at 2 h, which were significantly
(p = 0.013) superior to placebo [99]. AEs included dizzi-
ness, paresthesia, and sensations of heaviness, suggestive
of CNS-mediated effects [99].
In another phase II RCT (NCT00883051), oral doses
of 50, 100, 200, or 400 mg of lasmiditan likewise proved
significantly superior to placebo in reducing migraine
headache severity from moderate or severe at baseline to
mild or no headache at 2 h [12]. A significantly greater
proportion of patients was pain-free at 2 h after 200 mg
(19%, p = 0.032) and 400 mg (28%, p = 0.0007) of lasmidi-
tan [12].
SAMURAI (NCT02439320), a phase III RCT, evalu-
ated the efficacy of oral doses of lasmiditan (100 and
200 mg) [100] and demonstrated that a significantly (p <
0.001) greater proportion of patients was headache-free
at 2 h with 100 mg (28.2%) and 200 mg (32.2%) mg of
lasmiditan, compared to placebo (15.3%) [100]. Similar
results were obtained with the phase III RCT SPARTAN
(NCT02605174), but this study did not exclude patients
who had coronary artery disease, cardiac arrhythmias, or
uncontrolled hypertension [13]. The presence of cardio-
vascular risk factors in patients receiving lasmiditan did
not result in either decreased efficacy of lasmiditan or in
an increase in frequency of likely cardiovascular
treatment-emergent AEs [101]. Overall, the most com-
monly reported AEs in both phase III studies and in
the phase II study with the orally-administered lasmi-
ditan were dizziness, paresthesia, somnolence, fatigue,
nausea, lethargy (including a sensation of heaviness),
and vertigo [102].
The AEs of somnolence and fatigue suggest that lasmi-
ditan produces CNS-mediated effects [102, 103]. AEs
such as dizziness and vertigo associated with lasmiditan
could be generated through PNS-mediated effects since
vestibular organelles (e.g., cochlear inner hair cells and
vestibular hair cells) and the vestibular ganglion are ex-
tensively positive for 5-HT1F receptor immunoreactivity
[63]. PNS vestibular serotonergic activity is likely
associated with comorbidity of migraine and balance dis-
orders, vestibular migraine, and migraine-related tinnitus
or phonophobia [63, 65, 104, 105]. This concept is sup-
ported by the fact that IV serotonin infusions can elicit
plasma extravasation in specific inner ear tissues, ves-
tibular nerve, and associated ganglia [106].
Comparison of Ditans with Triptans
Although triptans are considered the gold standard for
the treatment of acute migraine, they still present some
drawbacks [74, 107]. Their mechanism is mediated by
the 5-HT1B receptor and includes vasoconstriction, so
they are contraindicated in patients who have cardiovas-
cular or cerebrovascular disease [75]. Moreover, triptans
are ineffective in approximately 40% of migraine attacks
and provide insufficient efficacy for about one-quarter of
patients [74, 107].
Ditans provide a different mechanism of action com-
pared to triptans in the treatment of a migraine attack.
A post-hoc analysis of pooled data from the phase III
SAMURAI and SPARTAN RCTs was undertaken to de-
termine whether the efficacy of lasmiditan differed be-
cause of prior triptan therapy response [108]. Regardless
of prior response to triptan use, patients taking lasmidi-
tan had greater efficacy than those taking placebo. This
benefit did not vary significantly between patients with a
good response and those with an insufficient response
(i.e., insufficient efficacy) to prior triptan use.
Treatment-emergent AEs were similar across subpopula-
tions regardless of prior triptan experience or response
to triptan use [108].
It is unclear if there is a CNS component to the effi-
cacy of triptans against migraine. Sumatriptan is poorly
lipophilic and does not cross the BBB to any appreciable
extent. CNS effects may contribute to the efficacy of
second-generation triptans (e.g. zolmitriptan, naratrip-
tan, rizatriptan, almotriptan, eletriptan, frovatriptan,
donitriptan, and avitriptan) [74]. However, literature
values for triptans’ distribution coefficients, indicative of
lipophilicity, vary considerably. Although these triptans
are somewhat more lipophilic than sumatriptan, their
values do not differ much, and their ability to penetrate
the CNS is poor when compared to CNS-active drugs
[74, 109, 110].
BBB efflux transporters such as P-glycoprotein (P-gp)
can substantially reduce the CNS concentration of trip-
tans [74, 111]. For example, the brain concentration of
eletriptan, the most lipophilic among the triptans, was
40 times greater in knock-out mice that did not express
the Mdr1a gene, which codes for P-gp, when compared
to the wild type; thus, eletriptan is considered to be a
“good” substrate for this efflux transporter [74, 111].
The brain:blood ratios of naratriptan and rizatriptan
were significantly reduced in mice expressing Mdr1a,
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suggesting that they also may be efflux transporter sub-
strates [111]. Other studies have concluded that there is
no significant correlation between lipophilicity coeffi-
cients of triptans and their efficacy in relieving migraine
[110]. These data suggest there may not be a major CNS
mechanism associated with triptans’ therapeutic effect in
migraine. Of note, neither the small molecule CGRP an-
tagonists, nor the large monoclonal antibodies [57] ap-
pear to have any clinically appreciable ability to cross
the BBB; thus, they may also not have a CNS component
to their efficacy.
Lasmiditan, on the other hand, is highly lipophilic and
capable of penetrating the BBB (Fig. 1e, Supplemental
Video) [10, 92, 112]. Studies with epithelial cell lines re-
vealed that lasmiditan had significant permeability across
cell membranes and thus would readily cross the BBB
[10]. In a preclinical study with mice receiving an IV in-
jection of 1 mg/kg of lasmiditan, the brain/plasma ratio
2 h after injection was 1.57, indicating a high degree of
CNS penetration for lasmiditan [10]. Lasmiditan crossed
the BBB of rats as evidenced by brain-to-plasma ratios
after IV and oral dosing, with CNS lasmiditan concen-
tration of 0.7 to 1.2 μg Eq/g vs. 0.9 μg Eq/g in the blood/
plasma [10]. These preclinical in vitro and in vivo animal
distribution observations indicated that lasmiditan can
cross the BBB and potentially alleviate migraine through
CNS mechanisms, possibly in combination with PNS ef-
fects (Fig. 1e,f, Supplemental Video) [10, 92, 112]. This
is consistent with the fact that the most common AEs
associated with lasmiditan are CNS-mediated effects
[102, 103]. However, the fact that lasmiditan has some
central effects does not prove that its efficacy against mi-
graine is mediated in the CNS. Preclinical and ex vivo
evidence suggested that lasmiditan may inhibit PNS and
CNS pain pathways, including the trigeminal nerve. In-
hibition is likely via decreased release of neuropeptides
and neurotransmitters such as CGRP and glutamate,
thereby attenuating local activity and neuronal firing
(Fig. 1e,f) [75].
A role for mitochondria?
It has been suggested that neuronal excitability and sus-
ceptibility to migraine could be due in part to mitochon-
drial dysfunction [113]. Studies using phosphorus
magnetic resonance spectroscopy showed impaired brain
oxidative energy metabolism related to mitochondrial
dysfunction in patients with migraine between and dur-
ing attacks [114, 115]. Conversely, a double-blind RCT
reported that a proprietary blend of Mg++, coenzyme
Q10 (designed to enhance mitochondrial function), and
riboflavin significantly reduced the burden of migraine
[116]. Epigenetic regulation of mitochondrial DNA could
represent a factor in the migraine pathogenesis [113].
Mitochondrial biogenesis helps maintain mitochon-
drial homeostasis, and the induction of mitochondrial
biogenesis has been shown to normalize mitochondrial
dysfunction [117]. In a series of in vitro and in vivo stud-
ies, it was found that activation of 5-HT1F receptors with
the selective agonists LY334370 and LY344864 increased
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone–
uncoupled oxygen consumption in renal proximal tubule
cells and increased the expression of mitochondrial pro-
teins [117]. Small interfering RNA knockdown of the 5-
HT1F receptor blocked mitochondrial biogenesis induced
by LY334370 and LY344864. Moreover, LY344864 en-
hanced the recovery of renal function in an animal
model of acute kidney injury by increasing mitochon-
drial biogenesis [117]. In other studies, LY344864 en-
hanced mitochondrial homeostasis in control and in 6-
hydroxydopamine lesioned mice, and increased loco-
motor activity in the lesioned mice [118]. These data
suggest mitochondrial dysfunction could have a role in
migraine pathophysiology, and that perhaps 5-HT1F re-
ceptor activity could help offset this dysfunction.
Treatment of human glomerular endothelial cells and
mouse glomerular endothelial cells with 5-HT1F receptor
agonists LY344864 or lasmiditan (0–500 nM) induced
mitochondrial biogenesis as evidenced by maximal mito-
chondrial respiration, increased nuclear- and
mitochondrial-encoded proteins, and increased mito-
chondrial number [119]. Collectively these studies
showed that agonists at the 5-HT1F receptor can en-
hance mitochondrial activity. The role mitochondrial
dysfunction may play in migraine pathophysiology re-
quires further investigation. Whether or not restoration
of normal mitochondrial function through 5-HT1F re-
ceptor activity plays a role in treatment for migraine also
needs additional research.
Conclusion
The discovery that activation of 5-HT1F receptors could
provide benefits without the cardiovascular risks associ-
ated with triptans was an important advancement in the
research on therapeutics for the treatment of migraine.
Evidence suggested lasmiditan PNS activation of the 5-
HT1F receptor can inhibit the release of CGRP from tri-
geminal afferent nerves in the PNS [63], thus mimicking
the behavior of triptans, CGRP antagonists, and CGRP
antibodies. Lasmiditan appears to cross the BBB and
may also act upon 5-HT1F receptors found in CNS sites
where the receptor potentially can modulate central
sensitization of the TNC and thalamus. Receptor activa-
tion may also activate elements of descending pain
modulation. Lasmiditan activation of the 5-HT1F recep-
tor does not mediate vasoconstriction, thus eliminating a
risk associated with triptans. Evidence is emerging that
agonists at the 5-HT1F receptor may also stimulate
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mitochondrial biogenesis, which potentially could help
mitigate migraine, although more research is needed.
Lasmiditan is a highly selective, lipophilic, high-affinity
5-HT1F agonist. While the precise mechanism of action
is unknown, preclinical in vitro and in vivo animal data
as well as ex vivo human evidence suggested that lasmi-
ditan exerts its therapeutic effects through agonist action
at PNS and CNS 5-HT1F receptors. This profile sug-
gested that lasmiditan may act through a mechanism not
fully engaged by current migraine therapies. Lasmiditan
may be beneficial for patients who have insufficient effi-
cacy, a contraindication, or an intolerability to other
current migraine therapeutics.
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